pet in sarcoma imaging treatment response ctos 2004 montreal j.f. eary, m.d. university of...
TRANSCRIPT
![Page 1: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/1.jpg)
PET in SarcomaImaging Treatment Response
CTOS 2004 MontrealJ.F. Eary, M.D.University of Washington
![Page 2: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/2.jpg)
Defining Tumor ResponseDefining Tumor Response
Conventional ImagingConventional Imaging Tumor shrinkage, disappearanceTumor shrinkage, disappearance Tumor qualitative changeTumor qualitative change
Clinical ExamClinical Exam
![Page 3: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/3.jpg)
Defining Tumor ResponseDefining Tumor Response
Clinical QuestionsClinical Questions1. How early can response be detected?1. How early can response be detected?
2. Which is the best treatment agent?2. Which is the best treatment agent?
3. Is an image response a surrogate for effectiveness of 3. Is an image response a surrogate for effectiveness of therapy?therapy?
4. Can patient outcome be inferred?4. Can patient outcome be inferred?
5. Does image response predict for patient outcome?5. Does image response predict for patient outcome?
![Page 4: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/4.jpg)
Tumor ResponseTumor Response
1. Slowed growth1. Slowed growth
2. Stasis2. Stasis
3. Necrosis - coagulative, liquefactive3. Necrosis - coagulative, liquefactive
4. Hemorrhage4. Hemorrhage
5. Serious fluid accumulations5. Serious fluid accumulations
6. Granulation tissue formation6. Granulation tissue formation
7. Scar formation7. Scar formation
8. Loss of vascularity8. Loss of vascularity
9. Loss of malignant elements9. Loss of malignant elements
![Page 5: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/5.jpg)
Re-Defining Tumor ResponseRe-Defining Tumor Response
Quantitative tumor biological parametersQuantitative tumor biological parameters1. Metabolism1. Metabolism
2. Receptor quantity2. Receptor quantity
3. Proliferation3. Proliferation
4. Uptake of thymidine agents4. Uptake of thymidine agents
![Page 6: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/6.jpg)
PET Contributions to Tumor PET Contributions to Tumor Response AssessmentResponse Assessment
1. Quantitative1. Quantitative
2. High spatial resolution2. High spatial resolution
3. Biologically relevant imaging agents3. Biologically relevant imaging agents
![Page 7: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/7.jpg)
Using PET to answer important questions in oncology–
What are the critical differences between normal, malignant, and treated tissue?
How can this information be used to understand the biochemical processes by which therapy kills or fails to kill cells?
From all of the available options, what will be the best treatment for an individual patient?
![Page 8: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/8.jpg)
PET Measurement as a Surrogate Endpoint for
Patient Outcome Tumor staging and grading, including
heterogeneity
Following response to treatment
Identifying the cause of resistance in the individual patient
Prediction / detection of normal tissue damage
Assessing metastases / metastatic potential
![Page 9: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/9.jpg)
Factors in Response and Factors in Response and ResistanceResistance
Surface Surface ReceptorsReceptors
OctreotideOctreotide
Proliferative Proliferative RateRate
Thymidine & Thymidine & AnalogsAnalogs
Glycolytic Glycolytic RateRate
FDGFDG
HypoxiaHypoxia
FMISO, EF1, FMISO, EF1, ATSMATSM
Efflux PumpsEfflux Pumps
MIBI, MIBI, Verapamil, Verapamil, ColchicineColchicine
Nuclear Nuclear ReceptorsReceptors
FES, FES, FDHTFDHT
![Page 10: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/10.jpg)
18FDG is the most important PET procedure
18FDG is the most important PET procedure
*
OHO
HOHO
F OH*
OHO
HOHO
F OH
2-fluoro-2-deoxy-D-glucose2-fluoro-2-deoxy-D-glucose
• FDG reflects altered tissue metabolism• FDG reflects altered tissue metabolism
More than just “grading” images.More than just “grading” images.
![Page 11: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/11.jpg)
High Grade Sarcoma: Near Complete High Grade Sarcoma: Near Complete Response to ChemotherapyResponse to Chemotherapy
Pre-rx
Post-rx
(SUV images, same scale)
![Page 12: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/12.jpg)
ESFT: Response assessed by ESFT: Response assessed by PETPET
Before chemotherapy After chemotherapy
![Page 13: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/13.jpg)
High Grade Sarcoma: High Grade Sarcoma: Tumor Progression during Tumor Progression during
ChemotherapyChemotherapy
Pre-rx
Post-rx
![Page 14: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/14.jpg)
Survival Based on Initial SUV
0.0
0.2
0.4
0.6
0.8
1.0
0 20 40 60
Time (months)
Pre SUV<7
Pre SUV>7Su
rviv
al P
rob
ab
ility
![Page 15: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/15.jpg)
Survival Based onPost-Chemotherapy SUV
0.0
0.2
0.4
0.6
0.8
1.0
0 20 40 60
Time (months)
Post SUV<4.2
Post SUV>4.2
Su
rviv
al P
rob
ab
ility
![Page 16: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/16.jpg)
Surviving
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50 60 70 80 90 100Time
Surviving
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50 60 70 80 90 100Time
Surviving
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50 60 70 80 90 100Time
Surviving
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50 60 70 80 90 100Time
a b
c d
SUV Grade
Diameter SUV + Grade
p = 0.026 p = 0.004
p = 0.171 p = 0.0009
SUV > 4
SUV ≤ 4 Grade I
Grade II/III
Diameter ≤ 9 cm
Diameter > 9 cm
FDG PET in Chondrosarcoma
![Page 17: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/17.jpg)
STS Survival Based on Change in Tumor SUV after Neoadjuvant Chemotherapy
![Page 18: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/18.jpg)
STS Survival based on 40% change in SUV after Neoadjuvant ChemoRx
![Page 19: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/19.jpg)
Can We Predict Response Can We Predict Response to Treatment?to Treatment?
Quantitative FDG imaging Quantitative FDG imaging FMISOFMISO C-11 ThymidineC-11 Thymidine C-11 VerapamilC-11 Verapamil
Quantitative FDG imaging Quantitative FDG imaging FMISOFMISO C-11 ThymidineC-11 Thymidine C-11 VerapamilC-11 Verapamil
![Page 20: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/20.jpg)
High Grade Sarcoma: High Grade Sarcoma: Heterogeneous Response to Heterogeneous Response to
ChemotherapyChemotherapy
Pre-rx
Post-rx
![Page 21: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/21.jpg)
3-D Ellipsoidal Model for 3-D Ellipsoidal Model for Homogeneous TumorsHomogeneous Tumors
Utilization U(x) as a Utilization U(x) as a function of position function of position ((xx) is given by) is given by
x1
x2
0.1
0.2
0.3
0.4
0.5
0.60.7
0.8
0.9
1
U(U(xx) = ) = gg[ [ (x-m)’A(x-m)(x-m)’A(x-m) ] ]
mm is the relative location is the relative location
AA is a shape matrix is a shape matrix
g g is a monotone level functionis a monotone level function
![Page 22: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/22.jpg)
Multivariate Survival AnalysisMultivariate Survival Analysis
Variable Variable (Standardized)(Standardized)
%Change in Risk%Change in Risk 95% C.I.95% C.I. P-valueP-value
SUVSUV 32.232.2 (13,54)(13,54) 0.00050.0005
HeterogeneityHeterogeneity(Elliptical)(Elliptical)
36.236.2 (11,68)(11,68) 0.00380.0038
HeterogeneityHeterogeneity(Boundary-(Boundary-Elliptical)Elliptical)
71.771.7 (-54,542)(-54,542) 0.420.42
N=179 (71 deaths)
Volume, RD, Boundary Morphology, Age: All not significant
![Page 23: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/23.jpg)
Liposarcoma PET StudiesLiposarcoma PET Studies
FDGFDG Blood VolumeBlood Volume ThymidineThymidine
![Page 24: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/24.jpg)
PET Imaging of Factors that PET Imaging of Factors that Limit Response to TherapyLimit Response to Therapy HypoxiaHypoxia
Direct effects: resistance to rads, chemoDirect effects: resistance to rads, chemo Indirect: genetic instabilityIndirect: genetic instability
VEGF, mutant p53VEGF, mutant p53
Multi Drug ResistanceMulti Drug Resistance viavia P-glycoprotein P-glycoprotein high energy requirementhigh energy requirement
![Page 25: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/25.jpg)
PET IMAGING
HIGH GRADE LEIOMYOSARCOMA
18F-FMISO
SUVMAX=3.2 SUVMAX=13.6
FDG
FMISO : identify treatment resistant tumorsFMISO : identify response/re-oxygenationFMISO : select patients for Tirpazamine therapy
![Page 26: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/26.jpg)
PET and Pharmacokinetics:[11C]-verapamil as a marker for the transport of
anti-HIV drugs
Hypothesis: Blocking P-gp will increase the delivery of anti-HIV
nucleosides to the brain
(Sagittal images of a macaque)
No inhibitor
After Cyclosporine (P-pg inhibitor)Brain Uptake
![Page 27: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/27.jpg)
[18F]-FBA-annexin V [18F]-FBA-annexin V ImagesImages
Rats were injected with 0.5 mCi and imaged for 10 min beginning at 60 min after injection. Apoptosis of liver was induced by injection of cycloheximide (5 mg/kg, 4 hr).
Normal Apoptosis
![Page 28: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/28.jpg)
Molecular Imaging AnswersMolecular Imaging Answers
Early indicators of the Early indicators of the effectiveness of therapy will effectiveness of therapy will
improve care--improve care--Reduce ineffective medication useReduce ineffective medication use
Reduce unhelpful proceduresReduce unhelpful proceduresReduce costReduce cost
Improve survival and quality of lifeImprove survival and quality of life
![Page 29: PET in Sarcoma Imaging Treatment Response CTOS 2004 Montreal J.F. Eary, M.D. University of Washington](https://reader034.vdocuments.site/reader034/viewer/2022051821/5697bfc21a28abf838ca4ab0/html5/thumbnails/29.jpg)
DNA
Microarrays
DNA
Microarrays